Neutrophil elastase inhibitors: A patent review and potential applications for inflammatory lung diseases (2010 - 2014)

Expert Opinion on Therapeutic Patents

Volumn 25, Issue 10, 2015, Pages 1145-1158

  Tsai, Yung Fong ^a,b   Hwang, Tsong Long ^a,c,d  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

elastase inhibitor; inflammatory diseases; neutrophil elastase; protease antiprotease imbalance

Indexed keywords

DEUTERIUM OXIDE; LEUKOCYTE ELASTASE INHIBITOR; PYRIMIDINONE DERIVATIVE; URACIL DERIVATIVE; LEUKOCYTE ELASTASE; PEPTIDE;

ADULT RESPIRATORY DISTRESS SYNDROME; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; EMPHYSEMA; HUMAN; IN VITRO STUDY; INFLAMMATORY DISEASE; LUNG DISEASE; PATHOGENESIS; PHYSIOLOGY; PNEUMONIA; PROTEIN DEGRADATION; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; INFLAMMATION; LUNG DISEASES; METABOLISM; PATENT; PATHOPHYSIOLOGY;

ANIMALS; DRUG DESIGN; HUMANS; INFLAMMATION; LEUKOCYTE ELASTASE; LUNG DISEASES; PATENTS AS TOPIC; PEPTIDES; PROTEINASE INHIBITORY PROTEINS, SECRETORY;

EID: 84942084241     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2015.1061998     Document Type: Review

References (105)

1. Nauseef WM. How human neutrophils kill and degrade microbes: an integrated view. Immunol Rev 2007;219:88-102
2. Henriksen PA. The potential of neutrophil elastase inhibitors as antiinflammatory therapies. Cur Opin Hematol 2014;21(1):23-8
3. Hoenderdos K, Condliffe A. The neutrophil in chronic obstructive pulmonary disease. Am J Respir Cell Molecul Biol 2013;48(5):531-9
4. Pipoly DJ, Crouch EC. Degradation of native type IV procollagen by human neutrophil elastase. Implications for leukocyte-mediated degradation of basement membranes. Biochemistry 1987;26(18):5748-54
5. Stein RL, Strimpler AM. Catalysis by human leukocyte elastase. Aminolysis of acyl-enzymes by amino acid amides and peptides. Biochemistry 1987;26(8):2238-42
6. Anderssen T, Halvorsen H, Bajaj SP, Osterud B. Human leukocyte elastase and cathepsin G inactivate factor VII by limited proteolysis. Thromb Haemost 1993;70(3):414-17
7. Turkington PT. Degradation of human factor X by human polymorphonuclear leucocyte cathepsin G and elastase. Haemostasis 1991;21(2):111-16
8. Doring G. The role of neutrophil elastase in chronic inflammation. Am J Respir Crit Care Med 1994;150(6 Pt 2):S114-17
9. Moraes TJ, Chow CW, Downey GP. Proteases and lung injury. Crit Care Med 2003;31(4 Suppl):S189-94
10. Stockley RA. The role of proteinases in the pathogenesis of chronic bronchitis. Am J Respir Crit Care Med 1994;150(6 Pt 2):S109-13
11. Wiener-Kronish JP, Gropper MA, Matthay MA. The adult respiratory distress syndrome: definition and prognosis, pathogenesis and treatment. Br J Anaesth 1990;65(1):107-29
12. Wang Y, Xiao Y, Zhong L, et al. Increased neutrophil elastase and proteinase 3 and augmented NETosis are closely associated with beta-cell autoimmunity in patients with type 1 diabetes. Diabetes 2014;63(12):4239-48.
13. Schrijver G, Schalkwijk J, Robben JC, et al. Antiglomerular basement membrane nephritis in beige mice. Deficiency of leukocytic neutral proteinases prevents the induction of albuminuria in the heterologous phase. J Experim Med 1989;169(4):1435-48
14. Yokoyama T, Tsushima K, Ushiki A, et al. Acute lung injury with alveolar hemorrhage due to a novel swine-origin influenza A (H1N1) virus. Int Med 2010;49(5):427-30
15. Tagami T, Tosa R, Omura M, et al. Effect of a selective neutrophil elastase inhibitor on mortality and ventilator-free days in patients with increased extravascular lung water: a post hoc analysis of the PiCCO Pulmonary Edema Study. J Inten Care 2014;2(1):67
16. Zeiher BG, Artigas A, Vincent JL, et al. Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med 2004;32(8):1695-702
17. Kroegel C, Foerster M. Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast. Expert Opin Investig Drugs 2007;16(1):109-24
18. Matera MG, Rogliani P, Calzetta L, Cazzola M. Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold? Drugs 2014;74(17):1983-92
19. Campbell EJ, Silverman EK, Campbell MA. Elastase and cathepsin G of human monocytes. Quantification of cellular content, release in response to stimuli, and heterogeneity in elastasemediated proteolytic activity. J Immunol 1989;143(9):2961-8
20. Lungarella G, Menegazzi R, Gardi C, et al. Identification of elastase in human eosinophils: immunolocalization, isolation, and partial characterization. Arch Biochem Biophys 1992;292(1):128-35
21. Tsuji N, Moriwaki S, Suzuki Y, et al. The role of elastases secreted by fibroblasts in wrinkle formation: implication through selective inhibition of elastase activity. Photochem Photobiol 2001;74(2):283-90
22. Liou TG, Campbell EJ. Nonisotropic enzyme-inhibitor interactions: a novel nonoxidative mechanism for quantum proteolysis by human neutrophils. Biochemistry 1995;34(49):16171-7
23. Faurschou M, Borregaard N. Neutrophil granules and secretory vesicles in inflammation. Microbes Infect 2003;5(14):1317-27
24. Perera NC, Schilling O, Kittel H, et al. NSP4, an elastase-related protease in human neutrophils with arginine specificity. Proc Nat Acad Sci USA 2012;109(16):6229-34
25. Zimmer M, Medcalf RL, Fink TM, et al. Three human elastase-like genes coordinately expressed in the myelomonocyte lineage are organized as a single genetic locus on 19pter. Proc Nat Acad Sci USA 1992;89(17):8215-19
26. Horwitz MS, Duan Z, Korkmaz B, et al. Neutrophil elastase in cyclic and severe congenital neutropenia. Blood 2007;109(5):1817-24
27. Taggart CC, Greene CM, Carroll TP, et al. Elastolytic proteases: inflammation resolution and dysregulation in chronic infective lung disease. Am J Respir Crit Care Med 2005;171(10):1070-6
28. Wiedow O, Meyer-Hoffert U. Neutrophil serine proteases: potential key regulators of cell signalling during inflammation. J Int Med 2005;257(4):319-28
29. Devaney JM, Greene CM, Taggart CC, et al. Neutrophil elastase up-regulates interleukin-8 via toll-like receptor 4. FEBS Lett 2003;544(1-3):129-32
30. Bank U, Ansorge S. More than destructive: neutrophil-derived serine proteases in cytokine bioactivity control. J Leukoc Biol 2001;69(2):197-206
31. Mihara K, Ramachandran R, Renaux B, et al. Neutrophil elastase and proteinase-3 trigger G protein-biased signaling through proteinase-activated receptor-1 (PAR1). J Biol Chem 2013;288(46):32979-90
32. Suzuki T, Yamashita C, Zemans RL, et al. Leukocyte elastase induces lung epithelial apoptosis via a PAR-1-, NFkappaB-, and p53-dependent pathway. Am J Respir Cell Molecul Biol 2009;41(6):742-55
33. Zhou J, Perelman JM, Kolosov VP, Zhou X. Neutrophil elastase induces MUC5AC secretion via proteaseactivated receptor 2. Mol Cell Biochem 2013;377(1-2):75-85
34. Hirche TO, Crouch EC, Espinola M, et al. Neutrophil serine proteinases inactivate surfactant protein D by cleaving within a conserved subregion of the carbohydrate recognition domain. J Biol Chem 2004;279(26):27688-98
35. Beaufort N, Leduc D, Rousselle JC, et al. Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. J Immunol 2004;172(1):540-9
36. Doring G, Frank F, Boudier C, et al. Cleavage of lymphocyte surface antigens CD2, CD4, and CD8 by polymorphonuclear leukocyte elastase and cathepsin G in patients with cystic fibrosis. J Immunol 1995;154(9):4842-50
37. Nadel JA. Role of mast cell and neutrophil proteases in airway secretion. Am Rev Respir Dis 1991;144(3 Pt 2):S48-51
38. Rogalski C, Meyer-Hoffert U, Proksch E, Wiedow O. Human leukocyte elastase induces keratinocyte proliferation in vitro and in vivo. J Invest Dermatol 2002;118(1):49-54
39. Renesto P, Chignard M. Enhancement of cathepsin G-induced platelet activation by leukocyte elastase: consequence for the neutrophil-mediated platelet activation. Blood 1993;82(1):139-44
40. Starcher B, O'Neal P, Granstein RD, Beissert S. Inhibition of neutrophil elastase suppresses the development of skin tumors in hairless mice. J Invest Dermatol 1996;107(2):159-63
41. Sun Z, Yang P. Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Lancet Oncol 2004;5(3):182-90
42. Gadek JE, Pacht ER. The proteaseantiprotease balance within the human lung: implications for the pathogenesis of emphysema. Lung 1990;168 Suppl:552-64
43. Perlmutter DH. Alpha-1-antitrypsin deficiency: biochemistry and clinical manifestations. Ann Med 1996;28(5):385-94
44. Silverman GA, Bird PI, Carrell RW, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Bio Chem 2001;276(36):33293-6
45. Sottrup-Jensen L. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem 1989;264(20):11539-42
46. Travis J. Structure, function, and control of neutrophil proteinases. Am J Med 1988;84(6A):37-42
47. Owen CA, Campbell EJ. The cell biology of leukocyte-mediated proteolysis. J Leuk Biol 1999;65(2):137-50
48. Sarker RS, John-Schuster G, Bohla A, et al. CARM1 regulates alveolar epithelial senescence and elastase-induced emphysema susceptibility. Am J Respir Cell Molecul Biol 2015. [Epub ahead of print]
49. Li Q, Li N, Liu CY, et al. Ezrin/Exocyst complex regulates mucin 5AC secretion induced by neutrophil elastase in human airway epithelial cells. Cell Physiol Biochem 2015;35(1):326-38
50. Sabater JR, Lee TA, Abraham WM. Comparative effects of salmeterol, albuterol, and ipratropium on normal and impaired mucociliary function in sheep. Chest 2005;128(5):3743-9
51. Juvelekian GS, Stoller JK. Augmentation therapy for alpha(1)-antitrypsin deficiency. Drugs 2004;64(16):1743-56
52. Hwang TL, Wang WH, Wang TY, et al. Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3. Bioorg Med Chem 2015;23(5):1123-34
53. Tsai YF, Yu HP, Chang WY, et al. Sirtinol inhibits neutrophil elastase activity and attenuates lipopolysaccharide-mediated acute lung injury in mice. Scientific Reports 2015;5:8347
54. Wright JL, Farmer SG, Churg A. Synthetic serine elastase inhibitor reduces cigarette smoke-induced emphysema in guinea pigs. Am J Respir Crit Care Med 2002;166(7):954-60
55. Korkmaz B, Horwitz MS, Jenne DE, Gauthier F. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev 2010;62(4):726-59.
56. Garcia SN, Van DNW, Carreno SC, et al. Peptides used in the treatment and/ or care of the skin, mucous membranes and/or scalp and their use in cosmetic or pharmaceutical compositions. CA2751436A1; 2010
57. DeMarco SJ, Moehle K, Henze H, et al. Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity. US8658604B2; 2014
58. Thongyoo P, Bonomelli C, Leatherbarrow RJ, Tate EW. Potent inhibitors of beta-tryptase and human leukocyte elastase based on the MCoTIII scaffold. J Med Chem 2009;52(20):6197-200
59. Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochimica et Biophysica Acta 1985;823(1):35-65
60. Lawrence DA, Stefansson SP. Mutant plasminogen activator-inhibitor type 1 (pai-1) and uses thereof. CA2233670C; 2012
61. Shinguh Y, Imai K, Yamazaki A, et al. Biochemical and pharmacological characterization of FK706, a novel elastase inhibitor. Eur J Pharmacol 1997;337(1):63-71
62. Kawabata K, Suzuki M, Sugitani M, et al. ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem Biophys Res Commun 1991;177(2):814-20
63. Kawabata K, Moore AR, Willoughby DA. Impaired activity of protease inhibitors towards neutrophil elastase bound to human articular cartilage. Ann Rheum Dis 1996;55(4):248-52
64. Iba T, Kidokoro A, Fukunaga M, et al. Pretreatment of sivelestat sodium hydrate improves the lung microcirculation and alveolar damage in lipopolysaccharideinduced acute lung inflammation in hamsters. Shock 2006;26(1):95-8
65. Jagwani D, Joshi P. A greener chemistry approach for synthesis of 4-(4-hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4 tetrahydropyrimidine-5-carboxylic acid ethyl ester. Int J Pharmaceut Sci Res 2015;6(2):783-90
66. Hansen G, Gielen-Haertwig H, Reinemer P, et al. Unexpected active-site flexibility in the structure of human neutrophil elastase in complex with a new dihydropyrimidone inhibitor. J Mol Biol 2011;409(5):681-91
67. Von Nussbaum F, Karthaus D, Anlauf S, et al. 4-(4-cyano-2-thioaryl) dihydropyrimidinones and their use. US8288402B2; 2012
68. GNAMM C, Oost T, Peters S, Rudolf K. Substituted Bicyclic Dihydropyrimidinones And Their Use As Inhibitors Of Neutrophil Elastase Activity. US0249129A1; 2014
69. FINCH HADLTD. Edwards C, Fitzgerald MF, et al. Multimers of pyrimidinone derivatives and their use as human neutrophil elastase inhibitors. EP1856059B1; 2010
70. Bergström L, Lönn H, Lundkvist M, Sjö P. Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors. US0003858A1; 2011
71. Ray NC, Finch H, Edwards C, O'connor E. Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors. EP2024367B1; 2010
72. Blench TJ, Edwards C, Heald RA, et al. Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhibitors. WO037809A1; 2013
73. Gielen-Haertwig H, Albrecht B, Keldenich J, et al. 1,4-diaryldihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors. EP1723121B1; 2012
74. Edwards C, Kulagowski J, Finch H. Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd. WO110858A1; 2011
75. Hansen P, Ivarsson M, Lawitz K, et al. 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. CA2650553C; 2014
76. Ainge D, Chapman D, Lindsjo M, et al. Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase. US0280048A1; 2010
77. Murugan A, Ashton M, Bergstrom LK, et al. 2-pyridone compounds used as inhibitors of neutrophil elastase. EP2483244A1; 2012
78. Andersson M, Hansen P, L ÖNN H, et al. 2-pyridone derivatives as neutrophil elastase inhibitors and their use. EP1663973B1; 2013
79. Oost T, FIEGEN D, GNAMM C, et al. Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity. US0057916A1; 2014
80. Shreder K, Hu Y, Fraser A, et al. Serine hydrolase inhibitors. EP2066662B1; 2012
81. Hsieh PW, Yu HP, Chang YJ, Hwang TL. Synthesis and evaluation of benzoxazinone derivatives on activity of human neutrophil elastase and on hemorrhagic shock-induced lung injury in rats. Eur J Med Chem 2010;45(7):3111-15
82. Shreder KR, Cajica J, Du L, et al. Synthesis and optimization of 2-pyridin-3-yl-benzo[d][1,3]oxazin-4-one based inhibitors of human neutrophil elastase. Bioor Med Chem Let 2009;19(16):4743-6
83. Hsieh PW, Hwang TL, Wu CC, et al. The evaluation of 2,8-disubstituted benzoxazinone derivatives as antiinflammatory and anti-platelet aggregation agents. Bioor Med Chem Let 2005;15(11):2786-9
84. Wong T, Groutas CS, Mohan S, et al. 1,2,5-Thiadiazolidin-3-one 1,1-dioxidebased heterocyclic sulfides are potent inhibitors of human tryptase. Arch Biochem Biophys 2005;436(1):1-7
85. Ahmed T, Abraham W. Hypersulfated disaccharides to treat elastase related disorders. CN103269585A; 2013
86. Groutas WC, Huang H, Epp JB, et al. Mechanism-based inhibition of human leukocyte elastase and cathepsin G by substituted dihydrouracils. Biochim Biophys Acta 1994;1227(3):130-6
87. Shiro T, Tobe M, Kubota K, et al. Uracil derivative and use thereof for medical purposes. US0179670A1; 2014
88. Isobe Y, Tobe M, Inoue Y, et al. Structure and activity relationships of novel uracil derivatives as topical antiinflammatory agents. Bioor Med Chem 2003;11(23):4933-40
89. Walker RT, Jones AS, De Clercq E, et al. The synthesis and properties of some 5-substituted uracil derivatives. Nucleic Acids Symp Ser 1980(8):s95-102
90. Bayerl T. Use of deuterium oxide as an elastase inhibitor. WO2009130615A3; 2010
91. Perona JJ, Craik CS. Structural basis of substrate specificity in the serine proteases. Protein Sci 1995;4(3):337-60
92. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004;303(5663):1532-5
93. Amulic B, Hayes G. Neutrophil extracellular traps. Cur Biol 2011;21(9):R297-8
94. Zawrotniak M, Rapala-Kozik M. Neutrophil extracellular traps (NETs)-formation and implications. Acta Biochim Pol 2013;60(3):277-84
95. Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol 2010;191(3):677-91
96. Branzk N, Lubojemska A, Hardison SE, et al. Neutrophils sense microbe size and selectively release neutrophil extracellular traps in response to large pathogens. Nat Immunol 2014;15(11):1017-25
97. Arendrup MC. Epidemiology of invasive candidiasis. Curr Opin Crit Care 2010;16(5):445-52
98. Low CY, Rotstein C. Emerging fungal infections in immunocompromised patients. F1000 Med Repor 2011;3:14
99. Almyroudis NG, Grimm MJ, Davidson BA, et al. NETosis and NADPH oxidase: at the intersection of host defense, inflammation, and injury. Front Immunol 2013;4:45
100. Hahn S, Giaglis S, Chowdhury CS, et al. Modulation of neutrophil NETosis: interplay between infectious agents and underlying host physiology. Semin Immunopathol 2013;35(4):439-53
101. Mesa MA, Vasquez G. NETosis. Autoimmune Dis 2013;2013:651497
102. Obermayer A, Stoiber W, Krautgartner WD, et al. New aspects on the structure of neutrophil extracellular traps from chronic obstructive pulmonary disease and in vitro generation. PLoS One 2014;9(5):e97784
103. Yoo DG, Floyd M, Winn M, et al. NET formation induced by Pseudomonas aeruginosa cystic fibrosis isolates measured as release of myeloperoxidase-DNA and neutrophil elastase-DNA complexes. Immunol Lett 2014;160(2):186-94
104. Branzk N, Papayannopoulos V. Molecular mechanisms regulating NETosis in infection and disease. Semin Immunopathol 2013;35(4):513-30
105. Caza T, Oaks Z, Perl A. Interplay of infections, autoimmunity, and immunosuppression in systemic lupus erythematosus. Int Rev Immunol 2014;33(4):330-63